Yan Qin Tang
Voorzitter bij Robeco Teda (Tianjin) Investment Management Co. Ltd.
Profiel
Mr. Yan Qin Tang is Independent Non-Executive Director at Mingyuan Medicare Development Co. Ltd., Vice President at China Health Insurance Research Association, Chairman at Lianhe Credit Information Service Co. Ltd., Chairman at Robeco Teda (Tianjin) Investment Management Co. Ltd., and Vice President at China Association For Labor Studies.
He is on the Board of Directors at Mingyuan Medicare Development Co. Ltd.
He received his undergraduate degree from Tianjin University.
Actieve functies van Yan Qin Tang
Bedrijven | Functie | Begin |
---|---|---|
China Health Insurance Research Association | Corporate Officer/Principal | 15-09-2011 |
Lianhe Credit Information Service Co. Ltd. | Voorzitter | 15-09-2011 |
Robeco Teda (Tianjin) Investment Management Co. Ltd. | Voorzitter | 15-09-2011 |
China Association For Labor Studies | Corporate Officer/Principal | - |
Eerdere bekende functies van Yan Qin Tang
Bedrijven | Functie | Einde |
---|---|---|
MINGYUAN MEDICARE DEVELOPMENT CO., LTD. | Directeur/Bestuurslid | 16-12-2014 |
Opleiding van Yan Qin Tang
Tianjin University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Mingyuan Medicare Development Co. Ltd.
Mingyuan Medicare Development Co. Ltd. BiotechnologyHealth Technology Mingyuan Medicare Development Co. Ltd. engages in provision of medicare solutions for the early detection and prevention of diseases particularly in China. It operates through the following segments: Protein Chips, Healthcare, Medical Centers Management, Individualized Target Therapy, and Bio-Drugs. The Protein Chips segment manufactures and distributes C-12 products to hospitals, medical centers, and life insurance companies in China. The Healthcare segment engages in the provision of sales and marketing campaign for HPV DNA testing kits and making important progress to register products for distribution to female patients at hospitals nationwide. The Medical Centers Management segment engages in the provision of healthcare services for residents living in cities. The Individualized Target Therapy segment specializes in molecular diagnostic kits for leukemia, lymphoma and individualised target cancer therapy. The Bio-Drugs segment engages in the development, production and commercialization of a new generation of non-specific nanotechnology immunomodulatory drugs known as non-cell Corynebacterium pavum products. The company was founded on May 8, 1989 and is headquartered in Hong Kong. | Health Technology |
China Health Insurance Research Association | |
Lianhe Credit Information Service Co. Ltd. | |
Robeco Teda (Tianjin) Investment Management Co. Ltd. | |
China Association For Labor Studies |